Studies were performed to evaluate the potential use of the bovine RIT 4237 rotavirus strain as a vaccine candidate against infection with human rotaviruses. Initial experiments revealed that colostrum-deprived piglets were susceptible to infection with several human strains, except for those belonging to subgroup 1. Subsequently, different immunization procedures with RIT 4237 were studied in this animal model. It was found that a two-dose administration, either given intramuscularly (twice) or once intramuscularly and once intragastrically, was necessary to induce a significant serum antibody response. Finally, the protective effect of the latter vaccination schedules against subgroup 2 and 3 rotavirus strains of human origin was evaluated by artificial challenge. In both cases, prior administration of live RIT 4237 significantly decreased fecal shedding of the challenge virus when compared with control animals.

A strain of human cytomegalovirus called Towne was isolated in WI-38 human fibroblast cell cultures from the urine of an infected infant. It was then passaged 125 times in WI-38, including three clonings, and a pool was prepared in the same cell substrate for use as a potential live attenuated vaccine. The Towne virus has a broad antigenicity and cross-reacts with the AD-169 strain. Several markers of the Towne virus were found which differentiated it from fresh isolates. One of these was resistance of the former to trypsin. The Towne virus was tested for freedom from oncogenicity or other harmful effects in preparation for tests in humans.

No abstract

No abstract

Extensive use of recombinants made from A/PR/8/34 (H0N1) and wild, virulent H3N2 viruses as live influenza vaccines has provided a number of viruses of defined virulence for man. Clinical symptoms produced by these strains have ranged from febrile influenza to local coryzal symptoms or nil. A study was therefore made of the extent to which the PR8 genome had been incorporated into that of a number of the recombinants. By RNA--RNA hybridization it seemed that recombinants which had 55 per cent of greater homology with the PR8 parent were likely to conform an acceptable standard of attenuation. Those with lesser homology were frequently, but not always, clinically virulent. The technique seemed potentially useful, therefore, for screening PR8 live vaccine recombinants in vitro before giving them to volunteers.